Autres langues Barinthus Biotherapeutics plc

Actions

BRNS

US91864C1071

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 10/05/2024			Varia. 5j.	Varia. 1 janv.
2,335 ^USD	-0,64 %		+7,11 %	-36,72 %

01/05	Barinthus Biotherapeutics plc nomme Leon Hooftman au poste de Chief Medical Officer, avec effet au début du mois de juin 2024	CI
18/04	BarinthuBarinthus Biotherapeutics plc annonce les premières données de l'essai de phase 1b/2 APOLLO sur le VTP-200 dans les infections persistantes à haut risque par le virus du papillome humain (HPV)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer	01/05
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer	01/05
Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024	01/05
Barinthus Cervical Lesions Treatment Study Meets Primary Objective -- Shares Rise After Hours	18/04
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections	18/04
BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus Infections	18/04
ADRs Advance; Connect Biopharma Climbs 19%	05/04
ADRs End Higher, Aesthetic Medical International Holdings Group Ltd. Climbs 35.5%	03/04
Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments	20/03
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones	05/01
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones	05/01
New partnership aims to advance vaccine against MERS coronavirus	21/12
Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD	09/11
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD	09/11
Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	09/11
CanSino Biologics Enrolls First Case in Recombinant Zoster Vaccine Trial in Canada	09/11
Barinthus Biotherapeutics plc(NasdaqGM:BRNS) added to NASDAQ Composite Index	08/11
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer	06/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Barinthus Biotherapeutics plc

Actions

BRNS

US91864C1071

Autres langues

Filtres